Premium
Adalimumab‐Induced Cutaneous Lupus Erythematosus in a 16‐Year‐Old Girl with Juvenile Idiopathic Arthritis
Author(s) -
West Emily S.,
Nanda Kabita,
Ofodile Ope,
Rutledge Joe,
BrandlingBennett Heather A.
Publication year - 2015
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.12576
Subject(s) - adalimumab , medicine , arthritis , dermatology , tumor necrosis factor alpha , juvenile , monoclonal , immunology , systemic lupus erythematosus , adverse effect , monoclonal antibody , antibody , disease , genetics , biology
Tumor necrosis factor α ( TNF ‐α) antagonists are used in the treatment of numerous autoimmune conditions. Adalimumab is the first monoclonal antibody to TNF ‐α and is used to treat juvenile idiopathic arthritis. A growing body of literature associates anti‐ TNF ‐α therapies with several adverse dermatologic manifestations, including drug‐induced lupus erythematosus (LE). We describe a case of cutaneous LE in a 16‐year‐old girl treated with adalimumab for juvenile idiopathic arthritis. The temporal association between her presenting symptoms and adalimumab initiation and gradual improvement after stopping biologic therapy suggest adalimumab‐induced cutaneous LE. With increasing use of anti‐ TNF therapies in children, the potential for drug‐induced LE should not be overlooked.